New hope for advanced cancer patients: JR8603 trial begins
Disease control
Recruiting now
This study tests a new drug called JR8603 in people with advanced solid tumors (like stomach or colorectal cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 94 adults will take part in this ear…
Phase: PHASE1 • Sponsor: JiaRay Group • Aim: Disease control
Last updated May 17, 2026 00:46 UTC